How much does a box of 2024 targeted drug Midostaurin cost?

The drug formulation midostaurin (Midostaurin) formulated by Novartis received regulatory approval in 2017 and was subsequently marketed as Rydapt. It is indicated for patients with newly diagnosed acute myeloid leukemia (AML) who carry mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. Midostulin is a potent inhibitor of multiple receptor tyrosine kinases that can effectively target various pathways, making it a promising antitumor agent with potential efficacy against a variety of solid and hematopoietic tumors.

Midostaurin may block normal and mutated kinases, which may lead to abnormal signaling pathways that lead to cancers such asAML and aggressive systemic mastocytosis (ASM). Administration of midostaurin did not produce any clinically relevant pharmacodynamic effects on the QTc interval compared with placebo in patients with advanced systemic mastocytosis (SM) or AML. Midostaurin may provide therapeutic benefits to patients when used in combination with chemotherapy.

Midostulin is the first targeted therapy for FLT3-mutated AML approved by the U.S. Food and Drug Administration (FDA) and is unique. Despite its benefits, midostaurin also poses challenges. It may not be effective in patients without FLT3 mutations, limiting its applicability. Additionally, controlling side effects such as gastrointestinal symptoms and potential drug interactions is critical.

The original drug of midostaurin is not currently on the market in China, nor is it covered by medical insurance, so the domestic price is unclear. Overseas, the European, Turkish and Indian versions of midostaurin are already on the market. The common packaging is 25mg*112 tablets, with prices ranging from RMB 10,000 to RMB 70,000, depending on exchange rate fluctuations. At the same time, there are also generic drugs for sale on the market. For example, the products of BDR Pharmaceuticals in India cost about 9,000 yuan per box, and their ingredients are basically the same as the original drugs.